Thermo Fisher Scientific, the world leader in serving science, introduced the Applied Biosystem QuantStudio Absolute Q-Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.

dPCR has quickly become the standard for nucleic acid quantification in oncology, cell and gene therapy development and other research applications because its absolute quantification enables higher accuracy and precision. Thermo Fisher recently acquired Combinati and its cutting-edge dPCR technology to rapidly develop and commercialize it alongside an expanding portfolio of assays.

Thermo Fisher Scientific is committed to innovation and providing the best technologies for our customers and help them accelerate innovation in areas including cancer research, rare diseases, and more. QuantStudio Absolute Q Digital PCR System is a much-needed solution in biotech and research-academia space,” said Amit Chopra, managing director, India, and South Asia, Thermo Fisher Scientific.

“The device overcomes the existing challenges of precision, operation, and turnaround time to provide an industry-best dPCR platform,” added Amit.

Unlike complex, multi-instrument workflows required for traditional dPCR, the QuantStudio Absolute Q System uses microfluidic array technology and simplified workflows, designed to improve data accuracy and consistency. The device supports the pharmaceutical fraternity in innovating disease management, advancing significantly in generating consistent and accurate data.

“QuantStudio Absolute Q solution is a fast and simple workflow that offers high-quality data with minimum hands-on time. It integrates all the necessary steps for dPCR—digitization, thermal cycling, and data acquisition—into a single instrument. The dPCR is already in use for longitudinal monitoring of cancer-driving mutations in liquid biopsy and precise quantification of gene inserts for cell therapy development,” said Kapil Sood, senior director, Life Sciences Solutions, Thermo Fisher Scientific

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion. Our Mission is to enable our customers to make the world healthier, cleaner, and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies, or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience, and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon.

Prime Healthcare, an award-winning physician-founded and physician-led health system, and Synchrony, a premier consumer financial services company, announced a partnership to offer new patient financing options at Prime Healthcare’s 45 hospitals in 14 states. In partnership with Synchrony, Prime Healthcare will offer patients another way to easily pay for healthcare over time with Synchrony’s CareCredit, a leading healthcare credit card, for pre-care, point-of-care and post-care payment.

By partnering with Synchrony to offer the CareCredit credit card, Prime Healthcare will establish a new payment option that enables price transparency and affordability, and empowers patients to access the care they need throughout their healthcare journey.

“Patient care will always be our number one priority,” said Sunitha Reddy, VP of Operations of Prime Healthcare. “Integrating care delivery with revenue cycle management is critical in an increasingly consumer-focused healthcare market. Implementing CareCredit solutions allows us the ability to offer flexible healthcare financing options that can help meet the unique and evolving needs of our patients while also improving their well-being and experience.”

Prime Healthcare patients can apply for the CareCredit credit card on a mobile device or computer, in a provider’s office, or over-the-phone. A credit decision is made within seconds and upon approval, applicants can use the credit card to pay bills immediately. Patients can select from short-term and long-term financing options including deferred interest if paid in full within 6,12,18 or 24 months and reduced APR with fixed monthly payments for 24, 36, 48 or 60 months.

“Synchrony’s CareCredit credit card was founded more than 30 years ago to help people pay for the healthcare they need or want for themselves and their families,” said Alberto Casellas, chief executive officer, Synchrony’s Health and Wellness Platform. “As out-of-pocket healthcare expenses continue to increase, patients are seeking providers that can address both the clinical and financial aspects of their healthcare experience. Our partnership with Prime Healthcare will help Prime Healthcare’s patients pay for the care they need while also streamlining the health system’s payments processes and financial workflows.”

Prime Healthcare patients who select CareCredit will have access to easy online account management tools, including payment reminders, and Synchrony’s award-winning customer service call center. Additionally, patients can use the CareCredit payment calculator to help estimate their monthly payments based on the amount of care financed and the offer selected.

The CareCredit credit card is a way for people to pay for care not covered by insurance, including elective procedures, copays, deductibles and coinsurance, often with special financing. Today, Synchrony’s CareCredit credit card is accepted at more than 250,000 provider and health-focused retail locations and has more than 6 million cardholder accounts.

About Synchrony

Synchrony is a premier consumer financial services company. We deliver a wide range of specialized financing programs, as well as innovative consumer banking products, across key industries including digital, retail, home, auto, travel, health and pet. Synchrony enables our partners to grow sales and loyalty with consumers. We are one of the largest issuers of private label credit cards in the United States; we also offer co-branded products, installment loans and consumer financing products for small- and medium-sized businesses, as well as healthcare providers. Synchrony is changing what’s possible through our digital capabilities, deep industry expertise, actionable data insights, frictionless customer experience and customized financing solutions.

About Prime Healthcare and Prime Healthcare Foundation
Prime Healthcare is an?award-winning health system?operating 45 hospitals and more than 300 outpatient locations in 14 states, providing over 2.6 million patient visits annually. It is one of the nation’s leading health systems with nearly 50,000 employees and physicians dedicated to providing the highest quality healthcare. Fourteen of the Prime Healthcare hospitals are members of the?Prime Healthcare Foundation, a 501(c)(3) not-for-profit public charity. Based in Ontario, California, Prime Healthcare is nationally recognized for award-winning quality care and has been named a Top 10 and Top 15 Health System by IBM Watson Health. Its hospitals have been named among the nation’s “100 Top Hospitals” 58 times and have received more Patient Safety Excellence Awards from Healthgrades than any other health system in the past six years.

FUJIFILM Healthcare Americas Corporation, a leading provider of endoscopic imaging and endosurgical solutions, announced the launch of its El-740D/S dual-channel endoscope. Fujifilm’s EI-740D/S is the first dual-channel endoscope cleared by the U.S. Food and Drug Administration (FDA) for use in both upper and lower gastrointestinal applications.

The EI-740D/S provides exceptional imaging quality and features dual channel diameters of 3.7mm and 3.2mm, enabling use of a range of endotherapy devices. The control handle is modeled after Fujifilm’s 700 series endoscopes which are designed to help enhance comfort without sacrificing control and to help reduce physician fatigue.

The distal end portion of the EI-740D/S dual channel endoscope is engineered to support easy insertion and device visualization, while its 210° upward angulation and short bending portion deliver precise maneuverability, enabling observation and treatment of areas typically difficult to approach. Like all Fujifilm 700 Series endoscopes, the EI-740D/S is equipped with Linked Color Imaging (LCI®) and Blue Light Imaging (BLI) light mode options for enhanced detection and characterization of lesions and adenomas.

“The availability of the EI-740D/S significantly expands the capabilities of gastroenterologists and colorectal surgeons across a wide range of therapeutic procedures,” said Taisuke Fujita, Vice President, Endoscopy, FUJIFILM Healthcare Americas Corporation. “This latest innovation draws on Fujifilm’s legacy of medical imaging and optical technology expertise. We are proud that FUJIFILM Healthcare Americas Corporation is continuing to deliver exciting, new advances to the field of minimally invasive diagnosis and surgery.”

The Fujifilm EI-740D/S is fully integrated with Fujifilm’s ELUXEO Endoscopy System and ELUXEO Surgical System. The ELUXEO Surgical System features a 4K UHD and Full HD imaging platform empowering enhanced procedural workflow, enabling surgical suite space optimization, and supporting new American Board of Surgeons (ABS) requirements for endoscopy.

Additional El-740D/S features:

• Dual channels allow for a broad range of devices that enable a full array of capabilities needed to perform ESD, from marking to coagulation, to be used with the endoscope, including Fujifilm’s ClutchCutter® and FlushKnife.
• The 3.2 mm instrument channel has an increased suction performance compared to the previous 2.8 mm instrument channel of the EG-530D dual channel gastroscope both with and without a device inserted into the channel.
• The newly designed water jet function which aids visualization for both diagnostic and therapeutic procedures. The target mucosa as well as the endotherapeutic device from the 3.2 mm instrument channel can be flushed during the procedure.

The EI-740D/S was developed in close collaboration with Apollo Endosurgery, Inc. to ensure compatibility with the OverStitch™ Endoscopic Suturing System. OverStitch enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures from a flexible endoscope. This new technology enables a secure approximation of tissue endoscopically and a wide range of less invasive solutions for physicians who treat defects in both the upper and lower GI tract of their patients. Additionally, physicians are leveraging endoscopic suturing to perform a variety of advanced bariatric procedures.

About Fujifilm

FUJIFILM Healthcare Americas Corporation is a leading innovator in diagnostic and enterprise imaging solutions designed to meet the evolving needs of healthcare across prevention, diagnosis, and treatment. Fujifilm’s medical imaging portfolio includes solutions for digital radiography, mammography, computed tomography, magnetic resonance imaging, ultrasound, endoscopy, and endosurgery. The Synapse® Enterprise Imaging portfolio provides healthcare professionals with the imaging and data access needed to deliver a complete patient record. REiLI®, Fujifilm’s artificial intelligence initiative, combines Fujifilm’s rich image -processing heritage with cutting-edge AI innovations to inspire a new tier of clinical confidence. The In-Vitro Diagnostic portfolio provides the golden standard of molecular based immunoassay technology for liver surveillance, cutting edge clinical diagnostic chemicals for leading laboratories across the country and diagnostic chemicals for OEM white labeling products. The company is headquartered in Lexington, Massachusetts.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship.

RaySearch Laboratories AB and IBA announce that they expand their partnership in proton therapy within the areas of FLASH radiotherapy, proton ARC therapy, and treatment of moving tumors.

RaySearch and IBA have had a strategic partnership on a global level since 2013. Over the years the collaboration has deepened and the combination of RayStation®* and IBA’s Proteus® systems are nowadays a well proven and de facto industry standard. Today, the majority of IBA’s Proteus centers have selected RayStation as treatment planning system and in total 27 centers around the world are equipped with a Proteus proton delivery system in combination with RayStation.

As part of the collaboration, the RayCare®* oncology information system from RaySearch, will be customized for optimal use together with the IBA delivery solutions. In both RayStation and RayCare, as well as in the IBA delivery solutions, joint features, dedicated software interfaces and modified graphical user interface components will allow for a seamless integration of the workflow with optimized performance. The result will be a turnkey solution for all software and hardware needed to deliver outstanding proton therapy treatments.

The extended collaboration includes the following areas:

Proton ARC therapy planning in RayStation specific for DynamicARC®1: The next evolution in proton delivery, promising easy delivery scheme, decreased delivery times, and improved dose conformality.

FLASH treatment planning in RayStation for Conformal FLASH®2: Combines the benefits of FLASH radiotherapy with the dosimetric benefits of proton radiation and the Bragg Peak. FLASH radiotherapy has the potential to revolutionize the future of cancer treatment by delivering ultra-high dose rate radiation, several orders of magnitude higher than what is currently used in conventional clinical radiotherapy.

Machine specific treatment planning tools for moving tumors: Masters and guarantees the dose conformality along the treatment course for patients with moving tumors by exploiting the machine characteristics to its full potential and providing dedicated imaging processing capabilities.

Johan Löf, founder and CEO, RaySearch, says: “Today the combination of RaySearch’s RayStation and IBA’s Proteus is an industry standard within proton therapy. With the now announced expanded partnership between our companies, we aim to take proton therapy to the next level by developing several innovative radiotherapy technologies that will significantly improve patient care.”

Olivier Legrain, CEO of IBA, says: “We continue to demonstrate year after year that our combined expertise is providing superior integrated proton therapy solutions for the benefits of clinicians allowing them to take best care of their patients.”

About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,500 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance. IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

About RaySearch
RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets worldwide its treatment planning system RayStation® and next-generation oncology information system RayCare®*. The latest additions to RaySearch’s product line are RayIntelligence® and RayCommand®. RayIntelligence is an oncology analysis system (OAS) that cancer clinics can use to collect, structure, and analyze data. The treatment control system (TCS) RayCommand® is designed as a link between the treatment machine and the systems for dose planning and oncology information. RaySearch software is used in about 2,600 clinics in over 65 countries. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003.

About RayStation
RayStation® is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare. By harmonizing the treatment planning, we enable better care for cancer patients worldwide.

About RayCare
The RayCare® oncology information system (OIS) is designed to support the many complex logistical challenges faced by today’s oncology clinics. RayCare is closely integrated with RayStation® and provides seamless access to all the powerful planning tools in RayStation, and RayCommand®. The system efficiently coordinates activities in radiation therapy and offers advanced features for clinical workflow automation, and adaptive radiation therapy. RayCare responds to the demand from clinics for a more user-friendly and workflow-oriented information system that can support the future of cancer care.

KORE, a global leader in Internet of Things (IoT) solutions and worldwide IoT Connectivity-as-a-Service (CaaS), unveiled a new Connected Health solution that enables customers to quickly incorporate the data telemetry component into their overall Connected Health offering, allowing their resources to focus on their primary business objective and value proposition.

“Orchestrating the data telemetry from patients, clinical trial participants, medical devices, and sensors is challenging,” said KORE’s EVP of Connected Health, Bryan Lubel. “Most connected health providers are forced to develop their own telemetry solution, when in fact, their real expertise is developing the analytics, workflow, care delivery optimization and use of the data to improve patient care and outcomes. We believe this solution will accelerate the time-to-market and adoption of large-scale remote patient monitoring initiatives.

KORE Connected Health Telemetry Solution™ (CHTS) is the next evolutionary step for remote data capture and was developed in response to heightened demand for remote patient care and monitoring. Over the last 24 months, the pandemic has emphasized the need for cost effective and efficient connected health monitoring. Remote patient monitoring service providers, provider networks, Clinical Research Organizations (CROs) and medical device OEMs have been seeking ways to accelerate and scale their remote monitoring initiatives.

CHTS provides integrated device management, secure BLE pairing of medical sensors with a cellular gateway, and secure data routing to a compliant temporary data repository that easily integrates connected health data into customer applications. Now, companies can get help with hardware selection and validation, access to a robust suite of supported medical devices and sensors, BLE pairing and device management at scale, network security that addresses cybersecurity issues and data telemetry as well as all regulatory and compliance controls.

In creating CHTS, KORE consulted with several healthcare and life sciences customers to address the common challenges and needs facing the industry. KORE’s customer Actigraph, the clinical research community’s most experienced provider of medical-grade biometric monitoring technology, is currently in pilot with CHTS.

“The data telemetry component in healthcare and life sciences is complex, highly regulated, and difficult to scale. In addition, the current economics can be a barrier to market growth,” said Jeremy Wyatt, CEO of Actigraph. “KORE’s CHTS will improve our ability to focus on helping our customers make better informed clinical decisions and alleviate the burden of managing the complex data telemetry challenge.”

KORE will be showcasing a full demo of the Connected Health Telemetry Solution in booth #1531 at Mobile World Congress – Los Angeles from October 26-28, 2021. Additionally, KORE will be hosting an informative Xtalks webinar on November 19, 2021 titled “Overcoming the Challenges of Implementing Connected Health Telemetry Initiatives”.

About KORE

KORE is a pioneer, leader, and trusted advisor delivering mission critical IoT solutions and services. We empower organizations of all sizes to improve operational and business results by simplifying the complexity of IoT. Our deep IoT knowledge and experience, global reach, purpose-built solutions, and deployment agility accelerate and materially impact our customers’ business outcomes.